Navigation Links
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Date:10/17/2007

renz, emtricitabine, and tenofovir DF, ATRIPLA should not be coadministered with SUSTIVA(R) (efavirenz), Emtriva(R) (emtricitabine), Viread(R) (tenofovir disoproxil fumarate), or Truvada(R) (emtricitabine/tenofovir DF). Due to similarities between emtricitabine and lamivudine, ATRIPLA should not be coadministered with drugs containing lamivudine, including Combivir(R) (lamivudine/zidovudine), Epivir(R) or Epivir-HBV(R) (lamivudine), Epzicom(TM) (abacavir sulfate/lamivudine), or Trizivir(R) (abacavir sulfate/lamivudine/zidovudine).

Serious psychiatric adverse experiences, including severe depression (2.4%), suicidal ideation (0.7%), nonfatal suicide attempts (0.5%), aggressive behavior (0.4%), paranoid reactions (0.4%), and manic reactions (0.2%), have been reported in patients receiving efavirenz. In addition to efavirenz, factors identified in a clinical study that were associated with an increase in psychiatric symptoms included a history of injection drug use, psychiatric history, and use of psychiatric medication. There have been occasional reports of suicide, delusions, and psychosis-like behavior, but it could not be determined if efavirenz was the cause. Patients with serious psychiatric adverse experiences should be evaluated immediately to determine whether the risks of continued therapy outweigh the benefits.

Fifty-three percent of patients reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams [6.2%], and hallucinations [1.2%]) when taking efavirenz compared to 25% of patients receiving control regimens. These symptoms usually begin during Days 1-2 of therapy and generally resolve after the first 2-4 weeks of therapy; they were severe in 2.0% of patients, and 2.1% of patients discontinued therapy. After 4 weeks of therapy, the prevalence of nervous system symptoms of at least moderate severity ranged from 5% to 9% in patients treated with regime
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
6. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
7. FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
10. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
11. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
... shows, investigational regimen resulted in 82 percent overall survival and 78 ... ... is presently being conducted in this ... patient population, LUGANO, Switzerland, June 9 In an ...
Cached Medicine Technology:Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 2Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 3Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 4
(Date:7/25/2014)... (HealthDay News) -- The human brain can preserve oxygen ... new study finds. Although dehydration significantly reduces ... found that the brain compensates by increasing the amount ... research has helped us understand a lot more about ... extreme conditions," study first author Steven Trangmar, a researcher ...
(Date:7/25/2014)... Ticket Down is a reliable source for ... at California Memorial Stadium. With the post-World Cup emotions ... organizers of the 2014 Guinness International Champions Cup have brought ... With teams representing La Liga, English Premier League, Serie A, ... best football players from around the world to 12 American ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 This ... current state of the Galactooligosaccharides (GOS) industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... Newyorktermlifeinsurance.org has released a new blog post ... policies. , The newly released blog post aims ... exam life insurance plans and traditional policies. The article ... to provide a simple guide for purchasing life coverage. ... be purchased online. Although traditional plans do not have ...
Breaking Medicine News(10 mins):Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2
... Work and economy related stress is taking its toll on ... by American Laser Centers, the largest provider of non-invasive aesthetic services ... part in the survey (47 percent) currently feel some stress, while ... , The physical toll of their stress is also ...
... , SPRINGFIELD, Ohio, Aug. 14 AdCare Health Systems, ... term care, home care and management company, today reported financial results ... Revenues for the quarter ended June 30, 2009 were $6,613,127 as ... of $596,591. The increase was mostly due to improved occupancy in ...
... avoid becoming overweight, researchers say , FRIDAY, Aug. 14 ... obesity epidemic by forbidding their kids to eat certain foods ... may actually be making the situation worse, researchers say. ... food choices that will allow them to maintain a healthy ...
... , , SALT LAKE CITY, ... and respected brands in the nutritional supplement industry, having provided consumers ... years, is excited to announce the seven lucky winners of the ... Each grand prize winner won a 10-day vacation for two ...
... , , RICHMOND, ... TSPT ), a specialty pharmaceutical company focused on the development ... in neuroscience, today announced financial results for the three and ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... , , , ... OXBO) today announced that the company has received approval to begin ... of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company,s ... approval from Swissmedic means that we can begin enrolling patients," said ...
Cached Medicine News:Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 2Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 3Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 4Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 5Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 6Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 7Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 8Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 9Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 10Health News:Restrictive Diet for Kids May Backfire 2Health News:Schiff Awards Seven Lucky Winners the 'Trip of a Lifetime' 2Health News:Schiff Awards Seven Lucky Winners the 'Trip of a Lifetime' 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 2Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 4Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 5Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 6Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 7Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 8Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 9Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 10Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 11Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 12Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 13Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 2Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 3
The precise, fully reusable R-100 Pullback Device is an invaluable tool during plaque volumetric analysis....
... you perform exams from cardiac to angio. ... no compromises. An ideal 31 centimeters square, ... of cardiovascular and interventional imaging. With a ... variety of vascular and interventional procedures. The ...
... The RX daytona is a fully ... field in bench top analysers offering many ... standing systems. With reusable glass cuvettes, on ... and reagents, the random access analyser can ...
Inquire...
Medicine Products: